Table 2 Clinical characteristics of NSCLC patients on the basis of the fifteen-mRNA signature in the training (n = 226, GSE31210) internal validation (n = 226, GSE30219) and external validation (n = 181, GSE50081) sets.
Characteristics | Training Set(n = 226, GSE31210) | Internal Validation Set(n = 226, GSE30219) | External Validation Set (n = 181, GSE50081) | ||||||
|---|---|---|---|---|---|---|---|---|---|
High-risk (n = 113) | Low-risk (n = 113) | P-value | High-risk (n = 113) | Low-risk (n = 113) | P-value | High-risk (n = 90) | Low-risk (n = 91) | P-value | |
Age (years) | |||||||||
< 60 | 51 | 45 | 0.5 | 38 | 50 | 0.133 | 12 | 15 | 0.677 |
≥ 60 | 62 | 68 | 75 | 63 | 78 | 76 | |||
Gender | |||||||||
Male | 61 | 44 | 0.03 | 104 | 88 | 0.005 | 41 | 41 | 1 |
Female | 52 | 69 | 9 | 25 | 49 | 49 | |||
Stage | |||||||||
I | 61 | 107 | < 0.01 | 71 | 90 | < 0.01 | 64 | 63 | 1 |
II | 52 | 6 | 42 | 23 | 26 | 27 | |||
